2 / 12
Page 12
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
allied
academies
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
T
he list of failed vaccines against respiratory and sexually
transmitted diseases in late clinical development is growing.
Recent failures include parenterally administered vaccines
against RSV and genital herpes (HSV2). Further, the emerging
pertussis infections and outbreaks on the background of a well-
established acellular pertussis vaccine is also alarming. Mucosal
surfaces are the port of entry for respiratory and sexually
transmitted diseases. Yet most vaccines evaluated or licensed
to date are parenterally administered and target systemic
responses. Targeting and triggering mucosal immunity may
bring to the table another efficient armof the immune response
that may prove essential in preventing or treating sexually
transited or respiratory infections. Nano Bio is developing an
intranasal nanoemulsion adjuvant/delivery (NE) that induces
mucosal Th17 responses and enhances homing of IgG and IgA
-secreting B-cells to localize in the mucosal tissues. Evaluation
of intranasal NE-RSV and NE-HSV2 vaccines in primary animal
models demonstrated that the vaccinated animals were
protected against disease, colonization, shedding, as well as
chronic infection in the case of HSV2 challenge. These data
suggest that mucosal immunity may be essential for successful
development of efficacious vaccines against these mucosal
pathogens and maybe improvement and expanding coverage
of existing vaccines such as pertussis and flu vaccines. Mucosal
Immunization and protection data from HSV2 in guinea pigs,
RSV in monkeys, and flu in ferrets will be shared.
Speaker Biography
For more than 25 years Dr. Fattom led research in vaccine discovery and development
against infectious diseases and addiction. After a 5 years tenure in vaccine research
at the NIH, under Dr. John Robbins, Dr. Fattom moved to the biotech industry, he
joined Nabi Biopharmaceuticals, to lead bacterial vaccines development. His work
on
Staphylococcus aureus
pathogenesis, determination of virulence factors, and
identifying protective antigens for developing a protective vaccine against this
pathogen are well recognized in the field. Nicotine vaccine, a second lead vaccine
developed by Dr. Fattom for smoking cessation was also developed through phase II
clinical trials. In 2010, Dr. Fattom joined NanoBio Corp. as a Sr. VP of vaccine research
and development. For the last 6 years, his efforts were focused on developing
intranasal vaccines against respiratory (Flu, RSV, Anthrax, and Pertussis), and sexually
transmitted diseases (Genital herpes HSV2, Chlamydia, and HIV). Target indication
for these vaccines is to protect against disease, carriage, shedding/transmission.
Dr. Fattom holds an Adjunct professor at the University of Michigan since 2012. He
authored >70 publications and >20 issued patents. He is a reviewer for NIAID and NIDA
grant applications and a reviewer for several journals including Vaccine, Infection and
Immunity, Human Vaccines & Immunotherapeutics, and NPJ Vaccine.
e:
ali.fattom@nanobio.comAli Fattom
Nano Bio Corp., USA
Can mucosal immunity succeed where other systemic immune responses failed?
Intranasal immunization using a Nanostat
TM
platform technology protected
against respiratory and sexually transmitted diseases in the appropriate animal
challenge models